• Mashup Score: 0

    Sanam Loghavi, Joseph D. Khoury; Disseminated blastic plasmacytoid dendritic cell neoplasm, Blood, Volume 126, Issue 4, 23 July 2015, Pages 558, https://doi.org

    Tweet Tweets with this article
    • Bone marrow involvement can be interstitial, nodular and leukemic or a-leukemic. This was an example of a leukemic case @JoeKhouryMD and I published in @BloodJournal #bloodwork https://t.co/Wm5sOb9j5D @ASH_hematology #ASHimagebank #WHOHEME #hemepath #bpdcn #BPDCNDay 3/ https://t.co/KGIlACzcci

  • Mashup Score: 2

    Follicular lymphoma (FL) is an indolent, B-cell, non-Hodgkin’s lymphoma with varying cytological appearance and clinical behavior. The genetic hallmark of FL is the t(14;18) translocation, and as a germinal center derived entity it is also characterized by somatic hypermutation of the immunoglobulin heavy chain (IgH) gene. In an attempt to correlate this molecular signature with the cytological…

    Tweet Tweets with this article
    • But.. b/c I’m a sucker for #hemepath history.. let me remind you the criteria for grading FL in WHO 2016 And show you what we mean when we refer to centrocytes (small cleaved cells) vs. centroblasts (large transformed cells +nucleoli) image from https://t.co/xjHP7lw477 #WHOHEME https://t.co/CyJSPQPgnr

  • Mashup Score: 0

    Proposed model of T-PLL development. Top: Projections from an ‘unaffected’ thymic emigrant (left) compared to the scenario of a post-thymic T-PLL precursor (right box) with inappropriate expression of TCL1 and deficient ATM. Effects of this postulated initiating core lesion of TCL1up/ATMdef on the key signaling branches and functions of ATM are highlighted by differential arrows. It includes…

    Tweet Tweets with this article
    • So why is TCL1 overexpressed in T-PLL? b/c inv(14)(q11q32) & t(14;14)(q11;q32) juxtapose TCL1A to TCR enhancer loci. Aberrant ⬆️TCL1 >> enhanced AKT signaling & increased cell proliferation & survival. Additional mutations cooperate. #WHOHEME https://t.co/yjlKkek4y8 @NatureComms https://t.co/FhVsxXsost

  • Mashup Score: 0

    The history of alemtuzumab use in multiple sclerosis The University of Cambridge has made a video on the history of alemtuzumab and published an article covering similar ground here. The beginnings of Alemtuzumab Campath-1H (now called alemtuzumab) was originally synthesized by Herman Waldmann at the Department of Pathology in Cambridge University (hence Cam-Path). Campath was licensed […]

    Tweet Tweets with this article
    • Now a bit of hx: Campath-1H (alemtuzumab) was originally synthesized by Herman Waldmann at the Department of Pathology in Cambridge University (hence Cam-Path 💡). Read about it here https://t.co/zVTAa4DaMR #WHOHEME @AaronGoodman33 https://t.co/X57XaSqlyX